Ticker Details
MacroGenics, Inc. Macrogenics Inc is a clinical-stage biopharmaceutical company. It focusses on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases.
IPO Date:	October 10, 2013
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$218.65M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.48 | 3.10%
Avg Daily Range (30 D):	$0.13 | 4.99%
Avg Daily Range (90 D):	$0.08 | 3.60%

Institutional Daily Volume
Avg Daily Volume:	.59M
Avg Daily Volume (30 D):	1.34M
Avg Daily Volume (90 D):	1.26M

Trade Size
Avg Trade Size (Sh.):	114
Avg Trade Size (Sh.) (30 D):	150
Avg Trade Size (Sh.) (90 D):	217

Institutional Trades
Total Institutional Trades:	2,285
Avg Institutional Trade:	$1.67M
Avg Institutional Trade (30 D):	$.77M
Avg Institutional Trade (90 D):	$1.17M
Avg Institutional Trade Volume:	.1M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.72M
Avg Closing Trade (30 D):	$.8M
Avg Closing Trade (90 D):	$.8M
Avg Closing Volume:	112.46K

News

Feb 26, 2026 @ 10:30 PM MacroGenics to Participate in Upcoming Investor Co... Source: Na

Feb 23, 2026 @ 11:14 PM MacroGenics Announces Pausing of Enrollment of New... Source: Macrogenics, Inc.

Jan 14, 2026 @ 8:30 AM [Latest] Global T-Cell Engagers Market Size/Share ... Source: Custom Market Insights

Aug 14, 2025 @ 8:21 PM MacroGenics Revenue Doubles in Q2 Source: Jesterai

Feb 6, 2025 @ 7:40 PM Investigation Alert: MacroGenics, Apellis Pharmace... Source: Johnson Fistel, Llp

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$-1.18	$-.22	$-1.18
Diluted EPS	$-1.18	$-.22	$-1.18
Revenue	$149.5M	$41.23M	$149.5M
Gross Profit
Net Income / Loss	$-74.62M	$-14.16M	$-74.62M
Operating Income / Loss	$-72.84M	$-12.1M	$-72.84M
Cost of Revenue	$M	$M	$M
Net Cash Flow	$-125.62M	$-22.91M	$-125.62M
PE Ratio